TrialEuropean heart journal2020

Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.

Robert F Storey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.